What is Apatinib mesylate?
Apatinib mesylate is a target therapy medication, developed and manufactured in China.
Apatinib mesylate is used to treat oncology patients suffering from various types of cancer, such as stomach cancer, lung cancer, liver cancer, and soft tissue sarcoma.
How is Apatinib mesylate used?
Apatinib mesylate tablets should only be used under the guidance of experienced doctors. Recommended dosage is 850 mg, taken once daily. The tablets are taken orally, half an hour after the meal with a glass of warm water. The tablets should be taken at the same time every day.
Treatment with Apatinib mesylate is generally well tolerated.
With regard to the adverse events, fatigue is the most common side effect among patients treated with Apatinib.
Other common side effects consisted of low white blood cell counts, low platelet counts and toxicity to the skin know as hand-foot syndrome.
Apatinib mesylate can be unsafe for certain patients.
Apatinib mesylate must not be taken by patients, who are allergic or hyper sensitive to any components of the medication.
Apatinib mesylate must not be taken by patients with contraindications (such as active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction).
The effect of the medication has not been studied in pregnant and lactating women. Please contact your physician for further clarifications.